Condition: Cardiomyopathy, Dilated · Sponsor: Cristina Avendaño Solá
Prospective, multicenter, randomized, placebo-controlled, double-blind clinical trial to evaluate safety and efficacy of candesartan in the prevention of the development of Dilated Cardiomyopathy (DCM) in genetic carriers of a DCM-causing variant without disease expression (asymptomatic)
This description comes directly from the study's public registry record.
Cristina Avendaño-Solá, MD, PhD · +34 91 1916479 · cavendano@salud.madrid.org
Ana Velasco-Iglesias, Msc,PhD · +34 91 1917867 · avelasco.idiphim@gmail.com
Always discuss trial participation with your own doctor first.
| Hospital Universitario Puerta de Hierro-Majadahonda | Majadahonda, Madrid, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05321875